Characteristics of Australian and New Zealand patients with chronic lymphocytic leukaemia: a lymphoma and related diseases registry report.

IF 1.8 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Internal Medicine Journal Pub Date : 2025-03-21 DOI:10.1111/imj.70037

Arina Martynchyk, Cameron Wellard, Eliza Chung, Simran K Bhopal, Zoe K McQuilten, Stephen P Mulligan, Stephen Opat, Erica M Wood, Eliza A Hawkes, Mary A Anderson

{"title":"Characteristics of Australian and New Zealand patients with chronic lymphocytic leukaemia: a lymphoma and related diseases registry report.","authors":"Arina Martynchyk, Cameron Wellard, Eliza Chung, Simran K Bhopal, Zoe K McQuilten, Stephen P Mulligan, Stephen Opat, Erica M Wood, Eliza A Hawkes, Mary A Anderson","doi":"10.1111/imj.70037","DOIUrl":null,"url":null,"abstract":"Background: Treatment of chronic lymphocytic leukaemia (CLL) has evolved significantly with the advent of targeted agents. Real-world analysis of patients with CLL provides a better understanding of treatment efficacy and toxicity and informs planning of future trials; however, Australasian studies are limited.Aims: Here we describe the demographics, disease characteristics, treatment and outcome for CLL patients enrolled in the Australia and New Zealand Lymphoma and Related Diseases Registry (LaRDR).Methods: This study included 365 patients aged ≥18 years with CLL diagnosed between January 2016 and May 2023.Results: Median age at diagnosis was 68 years, with 65% being male. Median follow-up was 15.2 months (range 0-78). 11q, 13q, 17p deletions and trisomy 12 were detected in 12%, 54%, 11% and 14% respectively. During the period of follow-up, 38% of patients commenced first-line therapy. The use of Bruton's Tyrosine Kinase inhibitors and B-cell lymphoma 2 inhibitors increased more than 10-fold following regulatory approval in 2020. Two-year progression-free and overall survival, measured from commencement of first-line therapy, were 67% (95% CI 55-76) and 87% (95% CI 78-93) respectively.Conclusion: The increasing use of targeted agents largely reflected availability; however, continuing use of chemoimmunotherapy following regulatory approval of targeted agents was noted in 29% of patients in 2022.","PeriodicalId":13625,"journal":{"name":"Internal Medicine Journal","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal Medicine Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/imj.70037","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Treatment of chronic lymphocytic leukaemia (CLL) has evolved significantly with the advent of targeted agents. Real-world analysis of patients with CLL provides a better understanding of treatment efficacy and toxicity and informs planning of future trials; however, Australasian studies are limited.

Aims: Here we describe the demographics, disease characteristics, treatment and outcome for CLL patients enrolled in the Australia and New Zealand Lymphoma and Related Diseases Registry (LaRDR).

Methods: This study included 365 patients aged ≥18 years with CLL diagnosed between January 2016 and May 2023.

Results: Median age at diagnosis was 68 years, with 65% being male. Median follow-up was 15.2 months (range 0-78). 11q, 13q, 17p deletions and trisomy 12 were detected in 12%, 54%, 11% and 14% respectively. During the period of follow-up, 38% of patients commenced first-line therapy. The use of Bruton's Tyrosine Kinase inhibitors and B-cell lymphoma 2 inhibitors increased more than 10-fold following regulatory approval in 2020. Two-year progression-free and overall survival, measured from commencement of first-line therapy, were 67% (95% CI 55-76) and 87% (95% CI 78-93) respectively.

Conclusion: The increasing use of targeted agents largely reflected availability; however, continuing use of chemoimmunotherapy following regulatory approval of targeted agents was noted in 29% of patients in 2022.

查看原文本刊更多论文

澳大利亚和新西兰慢性淋巴细胞白血病患者的特征：淋巴瘤和相关疾病登记报告

背景：随着靶向药物的出现，慢性淋巴细胞白血病（CLL）的治疗已经发生了显著的变化。对CLL患者的真实世界分析可以更好地了解治疗效果和毒性，并为未来试验的规划提供信息；然而，澳大利亚的研究是有限的。目的：在这里，我们描述了在澳大利亚和新西兰淋巴瘤及相关疾病登记处（LaRDR）登记的CLL患者的人口统计学、疾病特征、治疗和结局。方法：本研究纳入2016年1月至2023年5月诊断的365例年龄≥18岁的CLL患者。结果：诊断时的中位年龄为68岁，65%为男性。中位随访时间为15.2个月（0-78个月）。11q、13q、17p缺失和12三体的检出率分别为12%、54%、11%和14%。随访期间，38%的患者开始一线治疗。布鲁顿酪氨酸激酶抑制剂和b细胞淋巴瘤2抑制剂的使用在2020年获得监管批准后增加了10倍以上。从一线治疗开始，两年无进展生存率和总生存率分别为67% （95% CI 55-76）和87% （95% CI 78-93）。结论：靶向药物使用的增加在很大程度上反映了可获得性；然而，在监管机构批准靶向药物后，2022年有29%的患者继续使用化学免疫疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Internal Medicine Journal 医学-医学：内科

CiteScore

3.50

自引率

4.80%

发文量

600

审稿时长

3-6 weeks

期刊介绍： The Internal Medicine Journal is the official journal of the Adult Medicine Division of The Royal Australasian College of Physicians (RACP). Its purpose is to publish high-quality internationally competitive peer-reviewed original medical research, both laboratory and clinical, relating to the study and research of human disease. Papers will be considered from all areas of medical practice and science. The Journal also has a major role in continuing medical education and publishes review articles relevant to physician education.